Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: Implications for the development of new atrial fibrillation

Journal of Hypertension

Volumn 28, Issue 7, 2010, Pages 1534-1540

  Okin, Peter M ^a   Gerdts, Eva ^b   Wachtell, Kristian ^c   Oikarinen, Lasse ^d   Nieminen, Markku S ^d   Dahlöf, Björn ^e   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c Rigshospitalet   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

atrial fibrillation; ECG; hypertension; hypertrophy; left atrium

Indexed keywords

ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ELECTROCARDIOGRAPHY; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 77954350607     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328338c20e     Document Type: Article

References (36)

1. Gerdts E, Oikarinen L, Palmieri P, Otterstad JE, Wachtell K, Boman K, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Hypertension 2002; 39:739-743.
2. Benjamin EJ, Chen P-S, Bild DE, Mascette AM, Albert CM, Alonso A, et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 2009; 119:606-618.
3. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994; 89:724-730. (Pubitemid 24056200)
4. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried L, et al. Incidence and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455-2461.
5. Tsang TSM, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40:1636-1644.
6. Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41:218-223.
7. Thamilarasan M, Klein AL. Factors relating to left atrial enlargement in atrial fibrillation: 'chicken or the egg' hypothesis. Am Heart J 1999; 137:381-383.
8. Wachtell K, Devereux RB, Lyle PA, Okin PM, Gerdts E. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Ther Adv Cardiovasc Dis 2008; 6:507-513.
9. Nagarajarao HS, Penman AD, Taylor HA, Mosley TH, Butler K, Skelton TN, et al. The predictive value of left atrial size for incident ischemic stroke and all-cause mortality in African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2008; 39:2701-2706.
10. Tsang TSM, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol 2003; 42:1199-1205.
11. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TSM. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006; 47:2357-2363.
12. Sasson Z, Rasooly Y, Gupta R, Rasooly I. Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Can J Cardiol 1996; 12:257-263.
13. Gottdiener JS, Reda DJ, Williams DW, Matterson BJ. Left atrial size in hypertensive men: influence of obesity, race and age. J Am Coll Cardiol 1997; 29:651-658.
14. Dittrich HC, Pearce LA, Asinger RW, McBride R, Webel R, Zabalgoitia M, et al. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. Am Heart J 1999; 137:494-499.
15. Cioffi G, Mureddu GF, StefenelliC, de Simone G. Relationship between left ventricular geometry and left atrial size in patients with systemic hypertension. J Hypertens 2004; 22:1589-1596.
16. Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sampieri L, et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome. J Hypertens 2005; 23:875-882.
17. Tsioufis C, Taxiarchou E, Syrseloudis D, Chatzis D, Tsiachris D, Chatzistamatiou E, et al. Left ventricular mass but not geometry determines left atrial size in the early stages of hypertension. J Hum Hypertens 2009; 23:674-679.
18. Manolio TA, Gottdiener JS, Tsang TSM, Gardin JM, for the Cardiovascular Health Study Collaborative Research Group. Left atrial dimensions determined by M-mode echocardiography in black and white older (>65 years) adults (The Cardiovascular Health Study). Am J Cardiol 2002; 90:983-987.
19. Mattiolo AV, Bonatti S, Monopoli D, Zennaro M, Mattioli G. Influence of regression of left ventricular hypertrophy on left atrial size ad function in patients with moderate hypertension. Blood Press 2005; 14:273-278.
20. Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment. Losartan Intervention For Endpoint reduction in hypertension trial. Hypertension 2007; 49:1-6.
21. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.
22. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548-557.
23. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003; 107:2926-2931. (Pubitemid 36736634)
24. Healy JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832-1839.
25. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952.
26. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation: the LIFE Study. JAMA 2006; 296:1242-1248.
27. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
28. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25:417-423.
29. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37:161-186.
30. Wachtell K, Smith G, Gerdts E, Dahlöf B, Nieminen MS, Papdemetriou V, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol 2000; 85:466-472. (Pubitemid 30089623)
31. Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlöf B, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. Circulation 2002; 105:1071-1076. (Pubitemid 34212616)
32. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society for Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
33. Ilercil A, O'Grady MJ, Roman MJ, Paranicas M, Lee ET, Welty TK, et al. Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. J Am Soc Echocardiogr 2001; 14:601-611.
34. Bella JT, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002; 105:1928-1933.
35. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2003; 42:1206-1207.
36. Nattel S, Shiroshita-Takeshita A, Brundel BJ, Rivard L. Mechanisms of atrial fibrillation:lessonsfromanimal models.ProgCardiovascDis2005;48:9-28.